ZURICH (Reuters) – Novartis unveiled its long-expected plan to spin off all of its Alcon eye care devices business and launch a share buyback of up to $5 billion as the company sharpens its focus on prescription drugs, it said on Friday.
Source:: Reuters – Business News
